두개내 스텐트 시장 : 제품 유형, 재질, 코팅, 적응증, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Intracranial Stents Market is projected to grow by USD 4.15 billion at a CAGR of 5.26% by 2032.

Intracranial Stents Executive Summary

Intracranial stents are specialized neurovascular implants used to restore vessel patency, support coil embolization, divert blood flow from intracranial aneurysms, and manage selected cases of intracranial atherosclerotic disease. Demand is anchored in the global burden of stroke and cerebrovascular disorders, with the CDC reporting more than 795,000 strokes annually in the United States and ischemic stroke accounting for about 87% of cases.

The intracranial stents landscape is shaped by evidence-based patient selection, rapid neuroimaging, improved microcatheter delivery systems, and growing adoption of flow-diverter and braided stent technologies. Clinical value increasingly depends on procedural safety, vessel compatibility, antiplatelet management, operator experience, and long-term aneurysm occlusion or vessel patency outcomes.

Transformative Shifts in the Intracranial Stents Landscape

The intracranial stents landscape is shifting from broad intervention toward highly selective, imaging-guided therapy. Randomized evidence, including SAMMPRIS, materially changed treatment for symptomatic intracranial stenosis by emphasizing aggressive medical management for many patients, while subsequent registry and post-market data have supported safer outcomes when stenting is restricted to carefully selected, on-label populations treated by experienced operators.

At the same time, aneurysm management is being transformed by flow diversion, low-profile stent-assisted coiling platforms, braided designs, and surface-modified devices intended to reduce thrombogenicity. Hospitals are prioritizing comprehensive stroke center capabilities, multidisciplinary neurointerventional teams, advanced biplane angiography, and device portfolios that address tortuous anatomy, wide-neck aneurysms, and smaller distal vessels.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating measurable workflow advantages across the intracranial stents ecosystem. AI-enabled CT, CTA, MRI, and perfusion imaging tools help accelerate stroke triage, identify large-vessel occlusion, support aneurysm detection, and prioritize time-sensitive neurointerventional cases where minutes influence neurological outcomes.

Beyond diagnosis, AI supports 3D vessel segmentation, device sizing, computational flow modeling, and procedural planning for flow diversion or stent-assisted coiling. For manufacturers and healthcare providers, AI is improving design simulation, manufacturing quality control, case review, complaint analysis, registry management, and post-market surveillance, while regulatory expectations continue to require transparency, validation, cybersecurity, bias assessment, and real-world performance monitoring.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

North America remains a leading region for intracranial stents due to advanced stroke networks, high neurointerventional procedure volumes, FDA-regulated device pathways, comprehensive stroke center certification, and structured reimbursement coverage in major hospital systems. Europe follows with broad adoption across Germany, France, Italy, Spain, and the United Kingdom, supported by specialized neurovascular centers, mature clinical research activity, public health stroke initiatives, and increasing alignment under EU Medical Device Regulation requirements for clinical evidence and post-market surveillance.

Asia-Pacific is expanding as China, Japan, India, South Korea, and Australia invest in stroke care infrastructure, advanced imaging, specialist training, and local device manufacturing. Latin America shows growing demand in Brazil and Mexico, although access remains concentrated in large urban hospitals with angiography capacity and trained neurointerventional teams. The Middle East, led by GCC health investments, is scaling tertiary neurology, digital health, and medical tourism capacity, while Africa remains underserved but presents long-term clinical need as stroke burden, hypertension prevalence, diagnostic access, and referral pathways continue to evolve.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, adoption is supported by expanding private hospital networks, medical tourism, and gradual deployment of advanced endovascular stroke care in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines, although access differs significantly between capital-city hospitals and rural systems. The GCC is investing heavily in tertiary care, digital health, specialist recruitment, and internationally accredited hospitals, creating demand for advanced neurovascular devices in Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman.

The European Union provides a large regulated environment with high expectations for clinical evidence, post-market clinical follow-up, unique device identification, traceability, and conformity under the Medical Device Regulation. BRICS economies contribute scale through China, India, Brazil, Russia, and South Africa, with opportunities shaped by domestic manufacturing, public procurement, specialist availability, and reimbursement variability. G7 countries remain technology leaders with mature evidence generation, academic neurovascular centers, and established regulatory oversight, while NATO countries benefit from advanced hospital infrastructure, trauma-neurovascular readiness, and cross-border clinical collaboration across many member states.

Key Country Insights Across Major Intracranial Stents Markets

The United States leads commercialization due to FDA-authorized neurovascular technologies, large comprehensive stroke centers, advanced imaging availability, clinical trial activity, and high procedural capacity, while Canada benefits from centralized specialist care, public health system purchasing, and regional stroke networks. Mexico and Brazil show increasing demand in metropolitan hospitals, driven by private-sector investment and tertiary referral centers, but access remains uneven outside major cities because of specialist shortages, reimbursement limitations, and infrastructure gaps.

In Europe, the United Kingdom, Germany, France, Italy, and Spain support strong adoption through established stroke networks, specialist neurointerventional centers, and guideline-driven care, while Russia's market is shaped by localization priorities, public procurement, and variable regional access. China is scaling domestic innovation, hospital capacity, and stroke center development; India is expanding private-sector neurointervention and advanced imaging access; Japan benefits from advanced devices, high clinical discipline, and an aging population; Australia has strong tertiary care systems and organized stroke pathways; and South Korea combines high imaging penetration, sophisticated hospital technology adoption, and strong specialist expertise.

Actionable Recommendations for Industry Leaders

Industry leaders should align device development with evidence-based indications, neurovascular anatomy, and real-world operator needs. Priority actions include investing in lower-profile delivery systems, improved radiopacity, controlled deployment, resheathability, vessel-wall apposition, antithrombotic surface technologies, and clinical studies that document safety, patency, aneurysm occlusion, retreatment rates, ischemic events, hemorrhagic complications, and functional outcomes.

Commercial teams should focus on comprehensive stroke centers, physician training, proctoring programs, post-market evidence, and value-based messaging tied to reduced complications, improved procedural efficiency, and durable outcomes. Manufacturers should also strengthen AI-enabled planning partnerships, cybersecurity controls, supply chain resilience, regulatory readiness, registry participation, and country-specific reimbursement strategies to improve access across mature and emerging neurovascular systems.

Research Methodology

This executive summary is based on a structured review of verified secondary sources, including public health statistics from the CDC, WHO, and major stroke associations; regulatory information from agencies such as the FDA and European authorities; peer-reviewed clinical evidence; clinical guidelines; and publicly available hospital, registry, and policy data.

The methodology emphasizes triangulation across epidemiology, clinical outcomes, regulatory pathways, device innovation, regional healthcare infrastructure, reimbursement conditions, and specialist capacity. Insights were assessed for relevance to intracranial stents, flow diversion, stent-assisted coiling, and intracranial atherosclerotic disease treatment, with preference given to validated clinical, regulatory, and institutional sources.

Conclusion

The intracranial stents market is advancing through precision patient selection, safer device engineering, AI-enabled imaging, and expanding neurointerventional capacity. Opportunities are strongest where stroke systems, advanced imaging, trained specialists, referral networks, and reimbursement frameworks converge.

Future leadership will depend on combining clinical evidence with differentiated technology, real-world data, regulatory discipline, and region-specific access strategies. Organizations that demonstrate procedural safety, long-term outcomes, workflow value, and responsible adoption of AI-enabled neurovascular tools will be best positioned in this high-acuity intracranial stents segment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Intracranial Stents Market, by Product Type

• 7.1. Balloon Expandable
• 7.2. Self Expanding
  • 7.2.1. Braided
  • 7.2.2. Laser Cut

8. Intracranial Stents Market, by Material

• 8.1. Cobalt Chromium
• 8.2. Nickel Titanium
• 8.3. Stainless Steel

9. Intracranial Stents Market, by Coating

• 9.1. Bare Metal
• 9.2. Drug Eluting
  • 9.2.1. Paclitaxel
  • 9.2.2. Sirolimus

10. Intracranial Stents Market, by Indication

• 10.1. Aneurysm
  • 10.1.1. Fusiform
  • 10.1.2. Saccular
• 10.2. Stenosis
  • 10.2.1. Atherosclerotic
  • 10.2.2. Thrombotic

11. Intracranial Stents Market, by End User

• 11.1. Clinics
• 11.2. Hospitals

12. Intracranial Stents Market, by Distribution Channel

• 12.1. Direct Sales
  • 12.1.1. E Commerce
  • 12.1.2. Field Force
• 12.2. Distributor
  • 12.2.1. National Distributors
  • 12.2.2. Regional Distributors

13. Intracranial Stents Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Intracranial Stents Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Intracranial Stents Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Acandis GmbH
• 17.3. Asahi Intecc Co., Ltd.
• 17.4. Balt Group
• 17.5. Boston Scientific Corporation
• 17.6. Cerus Endovascular Ltd.
• 17.7. Contego Medical, Inc.
• 17.8. Cook Medical LLC
• 17.9. Evasc Neurovascular Enterprises ULC
• 17.10. Fluid Biomed Inc.
• 17.11. InspireMD, Inc.
• 17.12. Johnson & Johnson MedTech
• 17.13. Kaneka Corporation
• 17.14. Medtronic plc
• 17.15. MicroPort Scientific Corporation
• 17.16. MicroVention, Inc.
• 17.17. Obex Medical Ltd.
• 17.18. Oxford Endovascular Ltd.
• 17.19. Penumbra, Inc.
• 17.20. Perflow Medical Ltd.
• 17.21. Phenox GmbH
• 17.22. Rapid Medical Ltd.
• 17.23. Stryker Corporation
• 17.24. Terumo Corporation
• 17.25. TonBridge Medical Technology Co., Ltd.
• 17.26. W. L. Gore & Associates, Inc.